Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nat Med. 2023 Dec;29(12):3270. doi: 10.1038/s41591-023-02309-4.

Authors

Hatem Soliman¹, Deanna Hogue², Hyo Han³, Blaise Mooney⁴, Ricardo Costa³, Marie C Lee³, Bethany Niell⁴, Angela Williams⁴, Alec Chau⁴, Shannon Falcon⁴, Aixa Soyano³, Avan Armaghani³, Nazanin Khakpour³, Robert J Weinfurtner⁴, Susan Hoover³, John Kiluk³, Christine Laronga³, Marilin Rosa⁵, Hung Khong³, Brian Czerniecki³

Affiliations

¹ Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL, USA. Hatem.soliman@moffitt.org.
² Clinical Trials Office, Moffitt Cancer Center, Tampa, FL, USA.
³ Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL, USA.
⁴ Department of Radiology, Moffitt Cancer Center, Tampa, FL, USA.
⁵ Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

PMID: 36932246
DOI: 10.1038/s41591-023-02309-4

No abstract available

Publication types

Published Erratum